This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Updated from 1:32 p.m. EDT

Overall, clinical results and an array of announcements put health stocks in promising water on hump day -- though there's always an exception.

CollaGenex Pharmaceuticals (CGPI) fell on results of a phase II dose-finding study designed to evaluate the safety and determine the therapeutic range of incyclinide for the treatment of rosacea. The patients who were administered incyclinide didn't demonstrate a greater reduction in inflammatory lesions than the placebo arm at any point during the study, and thus the company is ending clinical development of incyclinide for rosacea patients. CollaGenex, which said it is planning to conduct additional development work for incyclinide for acne, fell $1.78, or 16%, to $9.35.

Other health care companies gave positive results, sending their stocks in the other direction. Alkermes (ALKS - Get Report) and Indevus Pharmaceuticals (IDEV) announced positive preliminary results from a phase IIa clinical study of ALKS 27, an inhaled formulation of trospium choloride, in patients with chronic obstructive pulmonary disease (COPD). The companies said single doses of ALKS 27 produced a rapid and statistically significant improvement in lung function over 24 hours compared with placebo.

Alkermes gained $1.24, or 7.4%, to $17.92, and Indevus up 0.9% at $6.68. They're both components of the Nasdaq biotechnology index, which was up 7.96 points, or 0.9%, to 858.21.

Also, Nektar Therapeutics (NKTR - Get Report) reported positive results from phase I and preclinical studies of NKTR-118, an oral therapy for opioid-bowel dysfunction (OBD), including opioid-induced constipation (OIC).
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WPI $85.73 0.00%
CGPI $0.00 0.00%
NOVC $0.07 0.00%
ALKS $39.75 0.00%
EBS $38.52 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs